TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a note issued to investors on Thursday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $1.88 on Thursday. TherapeuticsMD has a twelve month low of $1.86 and a twelve month high of $4.73. The stock’s fifty day simple moving average is $2.22 and its 200 day simple moving average is $2.30.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD at the end of the most recent quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.